Jump to content

Meclofenoxate

From Wikipedia, the free encyclopedia
(Redirected from Centrophenoxine)
Meclofenoxate
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)[1]
  • US: Not FDA approved
  • In general: ℞ (Prescription only)
Identifiers
  • 2-Dimethylaminoethyl (4-chlorophenoxy)acetate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.000.107 Edit this at Wikidata
Chemical and physical data
FormulaC12H16ClNO3
Molar mass257.71 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)OCC(=O)OCCN(C)C
  • InChI=1S/C12H16ClNO3/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11/h3-6H,7-9H2,1-2H3 ☒N
  • Key:XZTYGFHCIAKPGJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Meclofenoxate (INN, BAN; brand name Lucidril, also known as centrophenoxine) is a cholinergic nootropic used as a dietary supplement.[2][3][4] It is an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA).

In elderly patients, meclofenoxate has been shown to improve performance on certain memory tests.[5] Meclofenoxate also increases cellular membrane phospholipids.[citation needed] It is sold in Japan and some European countries, such as Germany, Hungary, and Austria, as a prescription drug.

Side effects

[edit]

Meclofenoxate is considered to be safe and high in tolerability. However, possible side effects may include, rarely, insomnia, dizziness, restlessness, muscle tremor, depression, nausea, muscle tension, and headache; these side effects may be due to overdosage and may indicate the need for the dosage to be reduced.

Research

[edit]

Meclofenoxate, as well as DMAE, have been found to increase the lifespans of mice by 26.5%.[6][7]

Brand names

[edit]

In addition to Lucidril, meclofenoxate has also been marketed under the brand names Amipolen, Analux, Brenal, Cellative, Centrophenoxin, Cerebron, Cerutil, Closete, Helfergin, Lucidryl, Lutiaron, Marucotol, Proserout, Proseryl, and Ropoxyl.[8] In the US, meclofenoxate is sold as a dietary supplement, although it is an unapproved drug.[4]

See also

[edit]

References

[edit]
  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 758–. ISBN 978-1-4757-2085-3.
  3. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 636–. ISBN 978-3-88763-075-1.
  4. ^ a b Cohen PA, Avula B, Khan I (October 2022). "The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements". Clinical Toxicology. 60 (10): 1156–1158. doi:10.1080/15563650.2022.2109485. PMID 35959800. S2CID 251516603.
  5. ^ Marcer D, Hopkins SM (May 1977). "The differential effects of meclofenoxate on memory loss in the elderly". Age and Ageing. 6 (2): 123–31. doi:10.1093/ageing/6.2.123. PMID 329662.
  6. ^ Donaldson T (1 January 2003). "A Brief History of Anti-aging Drugs". In Klatz R, Goldman B (eds.). The Science of Anti-aging Medicine. American Academy of Anti-Aging Med. pp. 66–. ISBN 978-0-9668937-3-1.
  7. ^ Hothschild R (August 1973). "Effect of dimethylamnioethyl p-chlorophenoxyacetate on the life span of male Swiss Webster Albino mice". Experimental Gerontology. 8 (4): 177–183. doi:10.1016/0531-5565(73)90024-7. PMID 4147092.
  8. ^ Zhou Y (22 October 2013). Drugs in Psychiatric Practice. Elsevier. ISBN 978-1-4831-9193-5.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Meclofenoxate&oldid=1244534407"